Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Ablynx extends nanobody alliance
January 2008
SHARING OPTIONS:

GHENT, BelgiumóAblynx, which works in the discovery and development of nanobodies, a novel class of antibody-derived therapeutic proteins, announced recently that its drug discovery and development alliance with Novartis has been extended for another year. Under the terms of the agreement, entered into in December 2005, the companies are collaborating to discover and develop novel nanobody-based therapeutics against disease targets that are difficult to address with conventional antibodies or their fragments. Novartis has exclusive right to develop and commercialize the nanobody products resulting from the collaboration.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.